BIOMÉRIEUX |
Market Closed -
Other stock markets
|
After market 01:40:18 pm | |||
| 95.5 EUR | +0.32% |
|
95.5 | 0.00% |
| May. 29 | BioMérieux: head injury test cleared by the FDA | CF |
| May. 28 | BioMérieux: FDA clearance for Vidas TBI test | CF |
| Sales 2024 * | 3.9B 4.24B | Sales 2025 * | 4.19B 4.56B | Capitalization | 11.25B 12.23B |
|---|---|---|---|---|---|
| Net income 2024 * | 468M 509M | Net income 2025 * | 529M 575M | EV / Sales 2024 * | 2.83 x |
| Net cash position 2024 * | 217M 236M | Net cash position 2025 * | 400M 435M | EV / Sales 2025 * | 2.59 x |
| P/E ratio 2024 * |
24.6
x | P/E ratio 2025 * |
21.7
x | Employees | 13,696 |
| Yield 2024 * |
0.93% | Yield 2025 * |
1.09% | Free-Float | 36.23% |
More Fundamentals
* Assessed data
More news
Latest transcript on bioMérieux
More recommendations
More press releases
More news
| 1 day | +0.95% | ||
| 1 week | +1.80% | ||
| Current month | -1.08% | ||
| 1 month | -3.32% | ||
| 3 months | -3.71% | ||
| 6 months | -2.54% | ||
| Current year | -4.47% |
1 week
93.55
97.55
1 month
91.80100.90
Current year
91.80108.90
1 year
84.54108.90
3 years
77.48133.20
5 years
67.45144.80
10 years
25.44144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 16-10-31 |
| Chairman | 50 | 04-04-15 | |
| Director of Finance/CFO | 47 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 06-09-14 | |
| Director/Board Member | 63 | 04-12-31 | |
| Chairman | 50 | 04-04-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.97% | 14 M€ | -3.05% | ||
| 0.26% | 1,083 M€ | +5.11% | ||
| 0.24% | 5 M€ | +4.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 95.5 | +0.32% | 75 849 |
| 24-06-05 | 95.2 | -0.88% | 86,720 |
| 24-06-04 | 96.05 | -0.31% | 64,910 |
| 24-06-03 | 96.35 | -0.82% | 72,272 |
| 24-05-31 | 97.15 | +2.91% | 690,760 |
Real-time Euronext Paris, June 06, 2024 at 07:30 am EDT
More quotes
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
2024-06-06
- Ex-dividend day for final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
95.2
EUR
Average target price
113.5
EUR
Spread / Average Target
+19.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.47% | 12.22B | |
| -3.75% | 8.16B | |
| +8.27% | 5.82B | |
| +33.10% | 5.72B | |
| -12.12% | 4.01B | |
| +14.18% | 2.75B | |
| -5.70% | 2.39B | |
| +18.60% | 2.05B | |
| -6.70% | 1.82B | |
| -3.89% | 1.49B |
- Stock Market
- Equities
- BIM Stock
